Xenetic Biosciences Statistics
Total Valuation
XBIO has a market cap or net worth of $3.79 million. The enterprise value is -$2.37 million.
Important Dates
The last earnings date was Tuesday, March 18, 2025, after market close.
Earnings Date | Mar 18, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
XBIO has 1.54 million shares outstanding. The number of shares has increased by 0.86% in one year.
Current Share Class | 1.54M |
Shares Outstanding | 1.54M |
Shares Change (YoY) | +0.86% |
Shares Change (QoQ) | +0.03% |
Owned by Insiders (%) | 7.28% |
Owned by Institutions (%) | 6.44% |
Float | 1.18M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 1.61 |
Forward PS | 2.73 |
PB Ratio | 0.67 |
P/TBV Ratio | 0.63 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.37
Current Ratio | 7.37 |
Quick Ratio | 6.89 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -50.12% and return on invested capital (ROIC) is -33.26%.
Return on Equity (ROE) | -50.12% |
Return on Assets (ROA) | -30.02% |
Return on Invested Capital (ROIC) | -33.26% |
Return on Capital Employed (ROCE) | -69.99% |
Revenue Per Employee | $1.25M |
Profits Per Employee | -$1.98M |
Employee Count | 2 |
Asset Turnover | 0.29 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -30.11% in the last 52 weeks. The beta is 2.18, so XBIO's price volatility has been higher than the market average.
Beta (5Y) | 2.18 |
52-Week Price Change | -30.11% |
50-Day Moving Average | 3.83 |
200-Day Moving Average | 3.96 |
Relative Strength Index (RSI) | 20.76 |
Average Volume (20 Days) | 6,638 |
Short Selling Information
The latest short interest is 4,534, so 0.29% of the outstanding shares have been sold short.
Short Interest | 4,534 |
Short Previous Month | 8,353 |
Short % of Shares Out | 0.29% |
Short % of Float | 0.39% |
Short Ratio (days to cover) | 0.96 |
Income Statement
In the last 12 months, XBIO had revenue of $2.50 million and -$3.96 million in losses. Loss per share was -$2.57.
Revenue | 2.50M |
Gross Profit | 2.50M |
Operating Income | -4.20M |
Pretax Income | -4.47M |
Net Income | -3.96M |
EBITDA | n/a |
EBIT | -4.20M |
Loss Per Share | -$2.57 |
Full Income Statement Balance Sheet
The company has $6.17 million in cash and n/a in debt, giving a net cash position of $6.17 million or $4.00 per share.
Cash & Cash Equivalents | 6.17M |
Total Debt | n/a |
Net Cash | 6.17M |
Net Cash Per Share | $4.00 |
Equity (Book Value) | 6.01M |
Book Value Per Share | 3.89 |
Working Capital | 5.69M |
Full Balance Sheet Cash Flow
Operating Cash Flow | -2.82M |
Capital Expenditures | n/a |
Free Cash Flow | -2.82M |
FCF Per Share | -$1.83 |
Full Cash Flow Statement Margins
Gross margin is 100.00%, with operating and profit margins of -168.16% and -158.39%.
Gross Margin | 100.00% |
Operating Margin | -168.16% |
Pretax Margin | -158.39% |
Profit Margin | -158.39% |
EBITDA Margin | n/a |
EBIT Margin | -168.16% |
FCF Margin | n/a |